Log in with your email address username.


[Correspondence] Everolimus in ileum neuroendocrine tumours – Authors’ reply

We thank Thomas Walter and Catherine Lombard-Bohas for their interest in our findings from the RADIANT-4 study.1 Eligible patients in our study had lung or gastrointestinal neuroendocrine tumours with radiological disease progression within 6 months before randomisation.1 Progression was determined by radiology report or by tumour measurements. Most patients (252 [83%] of 302) had disease progression within 3 months before randomisation, with a median time since progression of 1·6 months (unpublished).